On June 18, Legend Biotech declined 16.02% in regular trading, trading at $28.13/share, with turnover of $252 million. The sharp sell-off came after the company announced the pricing of a dilutive secondary offering.

Legend Biotech priced an underwritten public offering of 7.7 million American depositary shares at $29.35 each, raising gross proceeds of approximately $226 million. The offering price represented a notable discount to prior trading levels, triggering significant selling pressure as investors priced in the dilution impact. With shares now trading below the offering price at $28.13, the market reaction reflects concerns over shareholder dilution and potential overhang from new share supply.

The decline comes despite recent positive clinical developments, including early proof-of-concept data for its in vivo CAR-T candidate LB2501, which achieved a 100% objective response rate at the higher dose level in a Phase 1 lymphoma trial presented at the European Hematology Association Congress. However, the capital raise appears to have overshadowed the positive pipeline momentum in the near term.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)